075sek
-0,3 %
Date:2024-05-03Time:15:37:36Latest report:Q4-2023List:SpotlightTicker:PHAL
Market Cap:32 msekEnterprise Value:34 msekNet Sales:- msekEarnings:-4,40 msekEmployees:0ISIN:SE0003359710

Ratios

10-year key figure history for PharmaLundensis turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for PharmaLundensis with index and moving average MA50 and MA200.

Stockprice:0,75
MA50:0,75
MA200:0,54
Price/MA200:38,0 %
RSI (14):51,6
Price/MA50:0,4 %

Description

PharmaLundensi's business concept is to develop new and effective drugs for serious diseases that currently lack effective treatment. The company's main project is to develop a new drug for the lung disease chronic obstructive pulmonary disease (COPD). The projects also aim to develop drugs for other diseases, such as Alzheimer's and Parkinson's.

Biotechnology